|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/4155 | |
| A61K 31/4166 | |||
| A61K 45/06 | |||
| A61K 31/58 | |||
| A61P 35/00 | |||
| A61P 35/02 |
| (11) | Patento numeris | 3052098 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 14790344.7 |
| Europos patento paraiškos padavimo data | 2014-10-01 | |
| (97) | Europos patento paraiškos paskelbimo data | 2016-08-10 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-12-02 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/IB2014/064997 |
| Data | 2014-10-01 |
| (87) | Numeris | WO 2015/049650 |
| Data | 2015-04-09 |
| (30) | Numeris | Data | Šalis |
| 201361885053 P | 2013-10-01 | US | |
| 201461935404 P | 2014-02-04 | US |
| (72) |
CORNFELD, Mark J., US
KUMAR, Rakesh, US
MORRIS, Shannon Renae, US
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | ENZALUTAMIDE IN COMBINATION WITH AFURESERTIB FOR THE TREATMENT OF PROSTATE CANCER |
| ENZALUTAMIDE IN COMBINATION WITH AFURESERTIB FOR THE TREATMENT OF PROSTATE CANCER |